Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Diffuse Large B-Cell Lymphoma (ASH 2022) Basic Listing

Updates in Diffuse Large B-Cell Lymphoma
From the ASH Annual Meeting & Exposition

Oluwatobi Odetola, MD,
Conference Coverage
Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL
12/12/2023

Featuring Oluwatobi Odetola, MD

Featuring Oluwatobi Odetola, MD ...
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
Martin Hutchings, MD, PhD, Rigshospitalet, Copenhagen
Videos
Glofitamab Plus Polatuzumab Vedotin Shows Frequent, Durable Responses and Manageable Safety Among Patients With R/R DLBCL
12/12/2023

Featuring Martin Hutchings, MD, PhD

Featuring Martin Hutchings, MD, PhD ...
At the 65th ASH Annual Meeting, Martin Hutchings, MD, discussed updated data on the combination of glofitamab plus polatuzumab vedotin, which yielded high response rates and manageable safety among heavily pretreated patients with diffuse...
At the 65th ASH Annual Meeting, Martin Hutchings, MD, discussed updated data on the combination of glofitamab plus polatuzumab vedotin, which yielded high response rates and manageable safety among heavily pretreated patients with diffuse...
At the 65th ASH Annual Meeting,...
12/12/2023
Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities
12/11/2023

Featuring Narendranath Epperla, MD, MS

Featuring Narendranath Epperla, MD, M...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
Conference Coverage
R-CHOP Plus Tazemetostat Therapy Feasible Among Older Patients With Newly Diagnosed DLBCL
12/11/2023

Amber Denham

Amber Denham
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2...
12/11/2023
Oncology
Conference Coverage
Odronextamab Monotherapy Shows Promising Antitumor Activity Among Patients With R/R DLBCL Post CAR T-Cell Therapy
12/11/2023

Amber Denham

Amber Denham
Odronextamab monotherapy demonstrated encouraging antitumor activity and generally manageable safety among heavily pretreated patients with DLBCL who have progressed after CAR T-cell therapy, according to a phase 1 study.
Odronextamab monotherapy demonstrated encouraging antitumor activity and generally manageable safety among heavily pretreated patients with DLBCL who have progressed after CAR T-cell therapy, according to a phase 1 study.
Odronextamab monotherapy...
12/11/2023
Oncology
Charalambos Andreadis, MD 
Conference Coverage
Ibrutinib With Standard Conditioning and as Consolidation Therapy Following AutoHCT Well-Tolerated Among Patients With DLBCL
12/10/2023

Featuring Charalambos Andreadis, MD 

Featuring Charalambos Andreadis, MD  ...
At the 65th ASH Annual Meeting, Charalambos Andreadis, MD, presented on a phase 3 trial evaluating the efficacy of the addition of ibrutinib to autoHCT as conditioning and as consolidation therapy for patients with R/R ABC diffuse large...
At the 65th ASH Annual Meeting, Charalambos Andreadis, MD, presented on a phase 3 trial evaluating the efficacy of the addition of ibrutinib to autoHCT as conditioning and as consolidation therapy for patients with R/R ABC diffuse large...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Conference Coverage
Ibrutinib With and Following AutoHCT Well-Tolerated Among Patients With R/R Activated-B-Cell Subtype DLBCL
12/10/2023

Jordan Kadish

Jordan Kadish
The addition of ibrutinib with and following autoHCT showed tolerability and may improve progression-free survival among patients with relapsed/refractory activated B-cell subtype diffuse large B-cell lymphoma, according to a primary analysis...
The addition of ibrutinib with and following autoHCT showed tolerability and may improve progression-free survival among patients with relapsed/refractory activated B-cell subtype diffuse large B-cell lymphoma, according to a primary analysis...
The addition of ibrutinib with...
12/10/2023
Oncology
Conference Coverage
Mosunetuzumab Monotherapy Continues to Demonstrate Efficacy, Safety for Elderly/Unfit Patients With DLBCL
12/12/2022
Allison Casey
For patients with DLBCL unable to tolerate first-line chemoimmunotherapy, mosunetuzumab monotherapy continues to demonstrate promising efficacy with durable response with manageable safety with longer follow-up.
For patients with DLBCL unable to tolerate first-line chemoimmunotherapy, mosunetuzumab monotherapy continues to demonstrate promising efficacy with durable response with manageable safety with longer follow-up.
For patients with DLBCL unable...
12/12/2022
Oncology
Conference Coverage
Odronextamab Exhibits Clinically Meaningful Efficacy and Manageable Safety in Relapsed/Refractory DLBCL
12/12/2022
Allison Casey
Findings from a phase 2 trial show that odronextamab demonstrates clinically meaningful efficacy, durable complete responses, and tolerable safety in patients with relapsed/refractory DLBCL.
Findings from a phase 2 trial show that odronextamab demonstrates clinically meaningful efficacy, durable complete responses, and tolerable safety in patients with relapsed/refractory DLBCL.
Findings from a phase 2 trial...
12/12/2022
Oncology
Conference Coverage
Novel Agents Preferable to Standard Chemotherapy for Salvage Treatment in LBCL Progressing After CAR-T Therapy
12/11/2022

Janelle Bradley

Janelle Bradley
Salvage treatment with polatuzumab-containing and bispecific antibody-based regimens is preferable to standard chemotherapy for patients with relapsed/refractory LBCL, according to study findings.
Salvage treatment with polatuzumab-containing and bispecific antibody-based regimens is preferable to standard chemotherapy for patients with relapsed/refractory LBCL, according to study findings.
Salvage treatment with...
12/11/2022
Oncology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement